Maganin bushewar ido na farko tare da fasahar nanomicellar

"Muna farin cikin gabatar da CEQUA a matsayin sabon zaɓin magani ga 'yan Kanada fiye da miliyan shida da ke fama da bushewar cututtukan ido1," in ji Abhay Gandhi, Shugaba na Arewacin Amirka, Sun Pharma. "Wannan ƙaddamar da wani muhimmin ci gaba ne ga Sun Pharma yayin da muke fadada fayil ɗin mu na ido zuwa Kanada kuma yana nuna ƙaddamar da mu don samar da sabbin magunguna don tallafawa zaɓin mara lafiya da likita."

Baya ga yawaitar da ta yi a baya a tsakanin mutanen kasar Kanada, wani rahoto na baya-bayan nan daga Cibiyar Bincike da Ilimi ta Ido (CORE) ya nuna cewa yawan busasshen cututtukan ido yana karuwa saboda karuwar sanya abin rufe fuska, wanda zai iya haifar da bushewar tabo a kan. fuskar ido.2

"Muna farin cikin ganin sabon samfurin da ake samu yanzu ga yawancin mutanen Kanada da ke fama da keratoconjunctivitis sicca ko busassun cututtukan ido," in ji W. Bruce Jackson, MD, tsohon Farfesa da Shugaba, Sashen Ophthalmology, Jami'ar McGill da Jami'ar Ottawa. "CEQUA, tare da fasahar nanomicellar sa da kuma ƙara ƙarfin cyclosporine, na iya zama muhimmin ƙari ga zaɓuɓɓukan jiyya kamar yadda ƙwararrun kula da ido ke ƙoƙarin samun ƙarin jiyya na musamman."

 

Print Friendly, PDF & Email

Shafin Farko